{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:13:54Z","timestamp":1791332034396,"version":"4.3.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/yco.0b013e32835035b2","type":"journal-article","created":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T06:45:50Z","timestamp":1328078750000},"page":"96-102","source":"Crossref","is-referenced-by-count":148,"title":["Glutamatergic transmission in schizophrenia"],"prefix":"10.1097","volume":"25","author":[{"given":"Joshua","family":"Kantrowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Javitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210206","first-page":"108","article-title":"N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia Brain Res","volume":"83","author":"Kantrowitz","year":"2010","journal-title":"Bull"},{"key":"R2-6-20210206","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3371\/CSRP.4.3.6","article-title":"Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.","volume":"4","author":"Kantrowitz","year":"2010","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"R3-6-20210206","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.neuropharm.2010.10.022","article-title":"Metabotropic glutamate receptors: from the workbench to the bedside.","volume":"60","author":"Nicoletti","year":"2011","journal-title":"Neuropharmacology"},{"key":"R4-6-20210206","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/11533230-000000000-00000","article-title":"Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.","volume":"24","author":"Krystal","year":"2011","journal-title":"CNS Drugs"},{"key":"R5-6-20210206","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"R7-6-20210206","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pnpbp.2010.08.027","article-title":"Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia.","volume":"35","author":"Ohnuma","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R8-6-20210206","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.psychres.2009.11.008","article-title":"Glycine serum level in schizophrenia: relation to negative symptoms.","volume":"176","author":"Hons","year":"2010","journal-title":"Psychiatry Res"},{"key":"R9-6-20210206","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1440-1819.2010.02157.x","article-title":"No association between glutathione-synthesis-related genes and Japanese schizophrenia.","volume":"65","author":"Hanzawa","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"key":"R10-6-20210206","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.schres.2010.01.028","article-title":"No association between DAO and schizophrenia in a Japanese patient population: a multicenter replication study.","volume":"118","author":"Ohnuma","year":"2010","journal-title":"Schizophr Res"},{"key":"R11-6-20210206","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-009-1723-0","article-title":"Acute dopamine andor serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants.","volume":"208","author":"Leung","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"R12-6-20210206","first-page":"33","article-title":"Ketamine-induced disruption of verbal self-monitoring linked to superior temporal activation.","volume":"44","author":"Stone","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R13-6-20210206","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1176\/appi.ajp.2010.09030338","article-title":"Sensory deficits and distributed hierarchical dysfunction in schizophrenia.","volume":"167","author":"Leitman","year":"2010","journal-title":"Am J Psychiatry"},{"key":"R14-6-20210206","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.neuroimage.2011.06.045","article-title":"Ketamine effects on brain function: simultaneous fMRIEEG during a visual oddball task.","volume":"58","author":"Musso","year":"2011","journal-title":"Neuroimage"},{"key":"R15-6-20210206","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbr.2010.04.026","article-title":"Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia: gating of auditory-evoked potentials and prepulse inhibition.","volume":"213","author":"Broberg","year":"2010","journal-title":"Behav Brain Res"},{"key":"R16-6-20210206","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biopsych.2010.09.012","article-title":"Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance.","volume":"69","author":"Karlsgodt","year":"2011","journal-title":"Biol Psychiatry"},{"key":"R17-6-20210206","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.pnpbp.2011.03.016","article-title":"Altered DARPP-32 expression in the superior temporal gyrus in schizophrenia.","volume":"35","author":"Kunii","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R18-6-20210206","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.pnpbp.2011.07.010","article-title":"Profiles of DARPP-32 in the insular cortex with schizophrenia: a postmortem brain study.","volume":"35","author":"Nishiura","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R19-6-20210206","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/YPG.0b013e32833a201d","article-title":"Habituation in prepulse inhibition is affected by a polymorphism on the NMDA receptor 2B subunit gene (GRIN2B).","volume":"20","author":"Hokyo","year":"2010","journal-title":"Psychiatr Genet"},{"key":"R20-6-20210206","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1471-4159.2011.07282.x","article-title":"NMDA receptor regulates migration of newly generated neurons in the adult hippocampus via disrupted-in-schizophrenia 1 (DISC1).","volume":"118","author":"Namba","year":"2011","journal-title":"J Neurochem"},{"key":"R21-6-20210206","doi-asserted-by":"crossref","first-page":"859516","DOI":"10.1155\/2010\/859516","article-title":"Expressions of neuregulin 1beta and ErbB4 in prefrontal cortex and hippocampus of a rat schizophrenia model induced by chronic MK-801 administration.","volume":"2010","author":"Feng","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"R22-6-20210206","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.schres.2010.02.1069","article-title":"Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia.","volume":"119","author":"Kristiansen","year":"2010","journal-title":"Schizophr Res"},{"key":"R23-6-20210206","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/138161210790361452","article-title":"Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.","volume":"16","author":"Tsai","year":"2010","journal-title":"Curr Pharm Des"},{"key":"R24-6-20210206","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","article-title":"Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.","volume":"25","author":"Singh","year":"2011","journal-title":"CNS Drugs"},{"key":"R25-6-20210206","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S1461145709990939","article-title":"A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.","volume":"13","author":"Lane","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R26-6-20210206","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature"},{"key":"R27-6-20210206","first-page":"S320","article-title":"Glycine transporter type 1 (GLYT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia.","volume":"35","author":"Umbricht","year":"2010","journal-title":"Neuropharmacology"},{"key":"R28-6-20210206","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1021\/jm100210p","article-title":"Selective GlyT1 inhibitors: discovery of 4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenylmethanone (RG1678), a promising novel medicine to treat schizophrenia.","volume":"53","author":"Pinard","year":"2010","journal-title":"J Med Chem"},{"key":"R29-6-20210206","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","article-title":"High dose D-serine in the treatment of schizophrenia.","volume":"121","author":"Kantrowitz","year":"2010","journal-title":"Schizophr Res"},{"key":"R30-6-20210206","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.biopsych.2008.01.012","article-title":"A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy.","volume":"63","author":"Norberg","year":"2008","journal-title":"Biol Psychiatry"},{"key":"R31-6-20210206","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/appi.ajp.2009.08050757","article-title":"Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia.","volume":"166","author":"Fisher","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R32-6-20210206","first-page":"1901","article-title":"D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.","volume":"35","author":"Gottlieb","year":"2011","journal-title":"Schizophr Res"},{"key":"R33-6-20210206","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.","volume":"31","author":"Kinon","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R34-6-20210206","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2010.01.028","article-title":"Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade.","volume":"639","author":"Stefani","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"R36-6-20210206","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.biopsych.2010.12.023","article-title":"Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer 11C ABP688 and N-acetylcysteine challenge.","volume":"69","author":"Miyake","year":"2011","journal-title":"Biol Psychiatry"},{"key":"R37-6-20210206","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuroscience.2010.02.057","article-title":"Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation.","volume":"168","author":"Hackler","year":"2010","journal-title":"Neuroscience"},{"key":"R38-6-20210206","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.phrs.2009.12.010","article-title":"Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat.","volume":"61","author":"Chiusaroli","year":"2010","journal-title":"Pharmacol Res"},{"key":"R39-6-20210206","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1874104501004020003","article-title":"The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors.","volume":"4","author":"Smith","year":"2010","journal-title":"Open Med Chem J"},{"key":"R40-6-20210206","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/138161211795049633","article-title":"Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia.","volume":"17","author":"Ferraris","year":"2011","journal-title":"Curr Pharm Des"},{"key":"R41-6-20210206","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.neuropharm.2011.06.029","article-title":"Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain.","volume":"61","author":"Strick","year":"2011","journal-title":"Neuropharmacology"},{"key":"R42-6-20210206","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1601-183X.2010.00656.x","article-title":"Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology.","volume":"10","author":"DeVito","year":"2011","journal-title":"Genes Brain Behav"},{"key":"R43-6-20210206","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00213-011-2330-4","article-title":"Effects of low-dose D-serine on recognition and working memory in mice.","volume":"218","author":"Bado","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"R44-6-20210206","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-010-1794-y","article-title":"D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats.","volume":"209","author":"Shimazaki","year":"2010","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Current Opinion in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/YCO.0b013e32835035b2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:33:51Z","timestamp":1786048431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001504-201203000-00006"}},"subtitle":["from basic research to clinical practice"],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/yco.0b013e32835035b2","relation":{},"ISSN":["0951-7367"],"issn-type":[{"value":"0951-7367","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}